KR940001889A - Isoxazole derivatives for the treatment of irritable bowel syndrome - Google Patents

Isoxazole derivatives for the treatment of irritable bowel syndrome Download PDF

Info

Publication number
KR940001889A
KR940001889A KR1019930013372A KR930013372A KR940001889A KR 940001889 A KR940001889 A KR 940001889A KR 1019930013372 A KR1019930013372 A KR 1019930013372A KR 930013372 A KR930013372 A KR 930013372A KR 940001889 A KR940001889 A KR 940001889A
Authority
KR
South Korea
Prior art keywords
alkyl
hydrogen
bowel syndrome
irritable bowel
treatment
Prior art date
Application number
KR1019930013372A
Other languages
Korean (ko)
Other versions
KR100284462B1 (en
Inventor
싱 기다 자스완트
샤우스 존메너트
Original Assignee
리로이 휘테커
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리로이 휘테커, 일라이 릴리 앤드 캄파니 filed Critical 리로이 휘테커
Publication of KR940001889A publication Critical patent/KR940001889A/en
Application granted granted Critical
Publication of KR100284462B1 publication Critical patent/KR100284462B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

5-HTIA 작용물질 및 Ml 무스카린성 활성을 모두 갖는 일련의 이속사졸 유도체(I)를 사용한 과민성 대장 증후군(75)의 치료방법 및 그를 위해 적당한 제제가 제공되었다.A method of treating irritable bowel syndrome 75 with a series of isoxazole derivatives (I) having both 5-HTIA agonists and Ml muscarinic activity, and formulations suitable therefor, have been provided.

상기식에서, R은 수소, C1-C3알킬, 알릴, 또는 -CH2-이고 R1은 수소 C1-C3알킬, 알릴, -CH2-, 또는 -(CH2)n-X(여기에서, n은 1 내지 5이고; X는 임의로 치환된 페닐, C1-C3알콕시, 또는 C1-C3알킬티오임)이고; R2및 R3은 독립적으로 수소 C1-C3알킬, C1-C3알콕시, C1-C3알킬티오 할로 CN또는 페닐이거나; 함께 -(CH2)P-(여기에서, P는 3내지 6임)이고; Y는 -CH2-, -0- 또는 -SOm-(여기에서, m은 0,1또는 2임) 이다.Wherein R is hydrogen, C 1 -C 3 alkyl, allyl, or —CH 2 — And R 1 is hydrogen C 1 -C 3 alkyl, allyl, —CH 2 — Or-(CH 2 ) n -X wherein n is 1 to 5; X is optionally substituted phenyl, C 1 -C 3 alkoxy, or C 1 -C 3 alkylthio; R 2 and R 3 are independently hydrogen C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 1 -C 3 alkylthio halo CN or phenyl; Together are-(CH 2 ) P- , wherein P is 3 to 6; Y is -CH 2- , -0- or -SO m- , where m is 0, 1 or 2.

Description

과민성 대장 증후군의 치료를 위한 이속사졸 유도체Isoxazole derivatives for the treatment of irritable bowel syndrome

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (2)

포유동물의 과민성 대장 증후군의 치료 약제를 제조하기 위한 하기식I의 화합물 또는 약제학적으로 허용되는 그의 산 부가염 또는 용매화물의 용도.Use of a compound of formula I or a pharmaceutically acceptable acid addition salt or solvate thereof for the manufacture of a medicament for the treatment of irritable bowel syndrome in a mammal. 상기식에서, R은 수소, C1-C3알킬, 알릴, 또는 -CH2-이고 R1은 수소 C1-C3알킬, 알릴, -CH2-, 또는 -(CH2)n-X(여기에서, n은 1 내지 5이고; X는 임의로 치환된 페닐, C1-C3알콕시, 또는 C1-C3알킬티오임)이고; R2및 R3은 독립적으로 수소 C1-C3알킬, C1-C3알콕시, C1-C3알킬티오 할로 CN또는 페닐이거나; 함께 -(CH2)P-(여기에서, P는 3내지 6임)이고; Y는 -CH2-, -0- 또는 -SOm-(여기에서, m은 0,1또는 2임) 이다.Wherein R is hydrogen, C 1 -C 3 alkyl, allyl, or —CH 2 — And R 1 is hydrogen C 1 -C 3 alkyl, allyl, —CH 2 — Or-(CH 2 ) n -X wherein n is 1 to 5; X is optionally substituted phenyl, C 1 -C 3 alkoxy, or C 1 -C 3 alkylthio; R 2 and R 3 are independently hydrogen C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 1 -C 3 alkylthio halo CN or phenyl; Together are-(CH 2 ) P- , wherein P is 3 to 6; Y is -CH 2- , -0- or -SO m- , where m is 0, 1 or 2. 제1항에 있어서, 하기 화합물들로 이루어진 그룹으로부터 선택되는 화합물의 용도.Use of a compound according to claim 1 selected from the group consisting of the following compounds. 8-(이속사졸-5-일)-2-디프로필아미노-1,2,3,4-테트라하이드로나프탈렌; 8- (4-메틸이속사졸-5-일)-2-디프로필아미노-,1,2.3,4-테트라하이드로나프탈렌; 및 8- (3-메틸 이속사졸-5-일)-2-디프로필 아미노-1,2,3,4-테트라하이드로나프탈렌.8- (isoxazol-5-yl) -2-dipropylamino-1,2,3,4-tetrahydronaphthalene; 8- (4-methylisoxazol-5-yl) -2-dipropylamino-, 1,2.3,4-tetrahydronaphthalene; And 8- (3-methyl isoxazol-5-yl) -2-dipropyl amino-1,2,3,4-tetrahydronaphthalene. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019930013372A 1992-07-15 1993-07-15 Isoxazole derivatives for the treatment of irritable bowel syndrome KR100284462B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21097892A 1992-07-15 1992-07-15
US92-210978 1992-07-15
US91628192A 1992-07-17 1992-07-17
US916,281 1992-07-17

Publications (2)

Publication Number Publication Date
KR940001889A true KR940001889A (en) 1994-02-16
KR100284462B1 KR100284462B1 (en) 2001-03-02

Family

ID=67143280

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930013372A KR100284462B1 (en) 1992-07-15 1993-07-15 Isoxazole derivatives for the treatment of irritable bowel syndrome

Country Status (1)

Country Link
KR (1) KR100284462B1 (en)

Also Published As

Publication number Publication date
KR100284462B1 (en) 2001-03-02

Similar Documents

Publication Publication Date Title
RU96115142A (en) Derivatives of 5- (2-imidazolinilamino) benzimidazole, their production and use as agonists of alpha-2 adrenoceptors
KR950010888A (en) How to inhibit smooth muscle cell proliferation and restenosis
KR950016745A (en) Method of treating physiological symptoms and composition for same
KR920021556A (en) Rapamycin Dimer
FI850140L (en) CHEMICAL FOERENINGAR.
KR950010892A (en) How to suppress uterine fibrosis
KR900003151A (en) compound
KR950010893A (en) How to suppress endometriosis
KR950016723A (en) How to suppress autoimmune diseases
KR950016722A (en) Inhibition of LDL Oxidation and Atherosclerosis
KR950010889A (en) How to inhibit angiogenesis and angiogenic diseases
KR890011596A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for treating insomnia
KR960007592A (en) New pyrrolocarbazole
KR950010887A (en) How to inhibit cartilage degeneration
KR900016098A (en) Derivatives of Caffeic Acid and Pharmaceutical Compositions Containing the Same
KR950016734A (en) Inhibition of sexual prematurity
KR890008136A (en) Antimicrobial 9-Deoxo-9a-allyl and propargyl-9a-aza-9a-homoerythromycin A derivatives
KR890014112A (en) Use of quinolizine and quinolizine derivatives in the manufacture of a medicament for the treatment of cardiac arrhythmias
KR900014397A (en) Thieno-triazolo-diazepine sulfonyl derivatives, methods for their preparation and therapeutic compositions containing them
KR940001889A (en) Isoxazole derivatives for the treatment of irritable bowel syndrome
KR890008148A (en) New Sepharoseporin Compounds and Antibacterials
KR890009901A (en) 3-hydroxy-2- (4-methoxyphenyl) -5- (2-methylaminoethyl) -2,3-dihydro-5H-1,5-benzothiazepin-4-one derivative, its preparation and The use to the treatment
MX9206930A (en) NEW COMPOUNDS
KR890003755A (en) 7- (2-Methyl-4-aminopyrrolidinyl) naphthyridine and quinoline compounds
KR950016728A (en) How to suppress hirsutism and alopecia in women

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20031106

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee